Cervical Device Contraception-2 (Nanopaz) (NANOPAZ)

Bnai Zion Medical Center

Status and phase: Unknown; Phase 2; Phase 1

Conditions: Healthy

Treatments: Other: Nanopaz contraception device

Study type: Interventional

Funder types: Other

Identifiers

NCT00689494

BnaiZionMC-08-BP-003-CTIL

Details and patient eligibility

About

Measure blood progesterone by using cervical device contraception.

Full description

A very small cervical device that releases small amount of progesterone 20 mcgm/day.

The target of the research is to measure blood progesterone by using the cervical device.

This small device delivers progesterone by nanotechnology method.

Enrollment: 10 estimated patients

Sex: Female

Ages: 1 to 2 months old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• 10 healthy women are candidate for hysterectomy

Exclusion criteria

• Women with neoplastic malignancy disease or thrombophylia

Trial design

Primary purpose: Prevention

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)